Shifting the Paradigm to Enable Durable and Effective Cell & Gene Therapies
Vertical NanoStraw growth seen through a Scanning Electron Microscope (SEM)
NAVAN, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The Nanostraw technology, exclusively licensed from Stanford University, provides direct intracellular access into hard-to-transfect primary human cells for efficient delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.
NAVAN’s vision is to facilitate cell and gene therapies at the point of care. With the capability to streamline new therapy development and robust performance at scale, NanoStraws will greatly decrease costs, making clinical applications much more affordable and accessible.
World-class Leadership and Advisors
NAVAN has an experienced team, across multiple sites and countries, working with some of the world’s most highly-regarded institutions. Executing our vision every day, starting with the invention of the NanoStraw itself in a Stanford Physics laboratory to employing them to advance new life-saving, anti-cancer drugs towards the market, underscores our view that oftentimes the most innovative and disruptive technology comes from the strength of a disciplinary approach.
NAVAN is establishing research & commercial partnerships, academic collaborations, and other relationships with some of the most forward-thinking scientists and leaders across diverse and complementary disciplines, from materials science and physics to cell biology and industrial-scale engineering processes.
Read more about our Management team, Advisors and a few of our ongoing Collaborations.